MetaCap

Denali Therapeutics (DNLI) vs Iovance Biotherapeutics (IOVA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Iovance Biotherapeutics (IOVA) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 208.0% versus a gain of 2.5%. Over five years, DNLI leads with a -59.0% price change compared with -62.7% for IOVA. Iovance Biotherapeutics is the larger company by market cap ($3.19 billion vs $2.96 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DNLI+2.50%IOVA+208.04%
+592%+276%-40%
Nov 21, 20251 yearNov 20, 2026
DNLI-60.84%IOVA-63.36%
+12%-42%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DNLI versus IOVA key metrics
MetricDNLIIOVA
Share price$18.45$6.90
Market cap$2.96B$3.19B
1-day change+1.37%-5.61%
YTD return+11.75%+152.75%
1-year return+2.50%+208.04%
5-year return-59.02%-62.70%
EPS (TTM)$-1.72$-0.49
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$263.50M
Revenue growth (YoY)—+60.60%
Net income (latest FY)$-512.54M$-390.98M
Gross margin—34.28%
Operating margin—-153.08%
Net margin—-148.38%
52-week high$27.30$15.37
52-week low$15.34$2.08
Distance from 52-week high-32.42%-55.11%
Analyst consensusstrong_buybuy
Avg. price target upside+94.15%+110.14%
Average volume1.68M14.91M
Shares outstanding160.29M462.66M
Employees503975
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IOVA has outperformed DNLI by 205.5 percentage points over the past year.

About Denali Therapeutics

DNLI stock →

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees

About Iovance Biotherapeutics

IOVA stock →

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 975 employees

DNLI vs IOVA FAQ

Which is bigger, Denali Therapeutics or Iovance Biotherapeutics?

Iovance Biotherapeutics (IOVA) is larger, with a market capitalization of $3.19B compared with $2.96B for Denali Therapeutics (DNLI).

Which stock has performed better over the past year, DNLI or IOVA?

IOVA returned +208.04% over the past 12 months, compared with +2.50% for DNLI (price return, excluding dividends). Past performance does not predict future results.

Are Denali Therapeutics and Iovance Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons